Newsfile

The newsfeed available here is provided by our content partner Newswire Corp.. It is a major and wide-reaching newswire & news provider that provides information, press releases and multimedia content for media, journalists and the general public. ActusNews enjoys a high reputation and great popularity, especially among listed companies in its home market North America.

The NewsWire Hub ("X-Billboard") currently comprises six of the most important international news sources and is supplemented by a stock market information service and additional RNS News. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 30
5.505,35 S&P · 24,38 Vola-Index · 93.872,03 BTC · 1,13584 EURUSD
System-State: Number of processed items 173.579 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              

Newsfile Corp. is an important, trusted and reliable news source for private investors, investors and traders, which can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can access the respective news item and other analysis tools directly via the detailed views of the info cards.

NEWS
EXPLORER
CA14161Y2006
State: 25.04.2025 | 7AM
Do you already know our new terminal view? Click here.
FIGI: BBG00M0GNP68
CRDL
Cardiol Therapeutics Inc.
GICS: - · Sector: Life Sciences · Sub-Sector: -
NAME
Cardiol Therapeutics Inc.
ISIN
CA14161Y2006
TICKER
CRDL
MIC
XTSX
REUTERS
CRDL.TO
BLOOMBERG
CRDL CN
Wed, 16.04.2025       Cardiol Therapeutics
CA14161Y2006

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.D...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.04.2025       Cardiol Therapeutics
CA14161Y2006

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, w...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Mon, 03.03.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 20.02.2025       Cardiol Therapeutics
CA14161Y2006

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences compa...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 04.02.2025       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will pr...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Cardiol Therapeutics
CA14161Y2006

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trialsToronto, Ontario--(Newsfile Corp. - November 18...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 22.10.2024       Cardiol Therapeutics
CA14161Y2006

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Compa...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Fri, 11.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further ...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfu...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       Cardiol Therapeutics
CA14161Y2006

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its pre...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has ...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 24.09.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the ...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.09.2024       Cardiol Therapeutics
CA14161Y2006

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focuse...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 27.06.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual gen...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 25.06.2024       Cardiol Therapeutics
CA14161Y2006

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annu...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 13.06.2024       Cardiol Therapeutics
CA14161Y2006

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: ...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 14.05.2024       Cardiol Therapeutics
CA14161Y2006

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient e...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 02.04.2024       Cardiol Therapeutics
CA14161Y2006

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER t...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 21.02.2024       Cardiol Therapeutics
CA14161Y2006

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for ...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 15.02.2024       Cardiol Therapeutics
CA14161Y2006

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a...
Read More
Cardiol Therapeutics
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the international investor community, we would like to thank Newswire Corp. for providing the news and data feeds